Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 10.21 is 16% above its 5-year average of 8.79, near the low end of its 5-year range (0.04–42.80).
As of the fiscal period ended Friday, July 31, 2026. 0.20% below its 12-month average of 10.23.
Reported quarterly current ratio; no daily interpolation. Q3 FY2026 (2026-07-31): 10.21.
CURRENT RATIO
10.21
CURRENT RATIO AVG TTM
10.23
CURRENT RATIO AVG 3Y
13.33
CURRENT RATIO AVG 5Y
8.79
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-0.20%
CURRENT VS 3Y AVG
-23.37%
CURRENT VS 5Y AVG
+16.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.49
median of 706 covered companies
CURRENT VS SECTOR MEDIAN
+193.07%
vs the sector median at left
enGene Holdings Inc.
Market Cap
$122.93M
Current Ratio
10.21
TTM Avg
10.23
3Y Avg
13.33
5Y Avg
8.79
Market Cap
$121.00M
Current Ratio
0.18
TTM Avg
2.23
3Y Avg
2.69
5Y Avg
2.63
Market Cap
$125.34M
Current Ratio
0.86
TTM Avg
0.23
3Y Avg
0.62
5Y Avg
0.88
Market Cap
$118.89M
Current Ratio
13.55
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
Market Cap
$117.53M
Current Ratio
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$116.57M
Current Ratio
2.00
TTM Avg
1.45
3Y Avg
1.62
5Y Avg
1.71
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $122.93M | 10.21 | 10.23 | 13.33 | 8.79 |
| Cibus, Inc. (CBUS)vs › | $122.89M | 1.62 | 0.78 | 1.43 | 2.42 |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.00M | 0.18 | 2.23 | 2.69 | 2.63 |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | 0.86 | 0.23 | 0.62 | 0.88 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.89M | 13.55 | 17.30 | 10.78 | 9.73 |
| Entera Bio Ltd. (ENTX)vs › | $127.66M | 8.98 | 5.43 | 7.69 | 7.29 |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | 6.49 | 6.44 | 8.52 | 8.53 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | 2.00 | 1.45 | 1.62 | 1.71 |
| Genelux Corporation (GNLX)vs › | $116.81M | 2.39 | 3.50 | 2.69 | 1.97 |
| Coya Therapeutics, Inc. (COYA)vs › | $116.34M | 13.40 | 10.04 | 7.53 | 8.95 |
Current Ratio
10.21
Quick Ratio
10.21
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-07-31 | 10.21 |
| 2026-04-30 | 12.57 |
| 2026-01-31 | 11.75 |
| 2025-10-31 | 6.30 |
| 2025-07-31 | 10.34 |
| 2025-04-30 | 12.66 |
| 2025-01-31 | 17.16 |
| 2024-10-31 | 16.87 |
| 2024-07-31 | 19.52 |
| 2024-04-30 | 42.80 |
| 2024-01-31 | 12.97 |
| 2023-10-31 | 16.25 |
| 2023-07-31 | 0.04 |
| 2023-04-30 | 0.22 |
| 2022-12-31 | 0.57 |
| 2022-10-31 | 1.16 |
| 2022-07-31 | 2.05 |
| 2022-04-30 | 2.73 |
| 2021-12-31 | 4.79 |
